Re-defining pT4b buccal mucosa squamous cell carcinoma: Looking beyond palliation in select patients

Prateek V. Jain , Kapila Manikantan , Gary M. Clark , Indranil Mallick , Sanjoy Chatterjee , Indu Arun , Paromita Roy , Lateef Zameer , Pattatheyil Arun
{"title":"Re-defining pT4b buccal mucosa squamous cell carcinoma: Looking beyond palliation in select patients","authors":"Prateek V. Jain ,&nbsp;Kapila Manikantan ,&nbsp;Gary M. Clark ,&nbsp;Indranil Mallick ,&nbsp;Sanjoy Chatterjee ,&nbsp;Indu Arun ,&nbsp;Paromita Roy ,&nbsp;Lateef Zameer ,&nbsp;Pattatheyil Arun","doi":"10.1016/j.oor.2024.100616","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>Reports in the last 2 decades suggest that selected patients with masticator space invasion can be treated surgically with reasonable survival. This study is an attempt to identify prognosticators for disease free (DFS) and overall survival (OS) in surgically treated pT4 buccal mucosa squamous cell carcinoma (BMSCC) patients.</p></div><div><h3>Material and methods</h3><p>The cohort for this retrospective study comprised 213 patients with pT4a/b BMSCC, treated with curative intent surgery from August 2011 through December 2019. Depending upon masticator space invasion (MSI) patients were divided into 3 groups viz. pT4a, involvement of masseter and/or medial pterygoid (Low MSI) and involvement of lateral pterygoid and/or temporalis (High MSI).</p></div><div><h3>Results</h3><p>The median follow-up in this study was 45 (2–123) months. The 5-year DFS was 53 %, 42 % and 21 % for pT4a, Low MSI and high MSI groups, respectively. The 5-year OS was 68 %, 43 % and 21 % for these three groups. The MSI (HR 1.5, p = 0.113 for Low MSI, HR 2.98, p &lt; 0.001 for high MSI), perineural invasion (PNI) (HR 2.17, p = 0.001) and extranodal extension (ENE) (HR 2.74, p = 0.001) predicted poor DFS on multivariate analysis. OS was worse in patients with MSI (HR 1.86, p = 0.020 for Low MSI, HR 3.46, p &lt; 0.001 for high MSI), PNI (HR 2.48, p &lt; 0.001) and ENE (HR 3.02, p = 0.001) on multivariate analysis. Adjuvant treatment improved both OS and DFS.</p></div><div><h3>Conclusion</h3><p>Select patients with masticator space involvement can benefit from aggressive treatment. Radiation with or without chemotherapy in adjuvant setting can further improve prognosis in these patients.</p></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277290602400462X/pdfft?md5=2b2634e543c75e4c4356e750abff3b1a&pid=1-s2.0-S277290602400462X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Oncology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S277290602400462X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

Reports in the last 2 decades suggest that selected patients with masticator space invasion can be treated surgically with reasonable survival. This study is an attempt to identify prognosticators for disease free (DFS) and overall survival (OS) in surgically treated pT4 buccal mucosa squamous cell carcinoma (BMSCC) patients.

Material and methods

The cohort for this retrospective study comprised 213 patients with pT4a/b BMSCC, treated with curative intent surgery from August 2011 through December 2019. Depending upon masticator space invasion (MSI) patients were divided into 3 groups viz. pT4a, involvement of masseter and/or medial pterygoid (Low MSI) and involvement of lateral pterygoid and/or temporalis (High MSI).

Results

The median follow-up in this study was 45 (2–123) months. The 5-year DFS was 53 %, 42 % and 21 % for pT4a, Low MSI and high MSI groups, respectively. The 5-year OS was 68 %, 43 % and 21 % for these three groups. The MSI (HR 1.5, p = 0.113 for Low MSI, HR 2.98, p < 0.001 for high MSI), perineural invasion (PNI) (HR 2.17, p = 0.001) and extranodal extension (ENE) (HR 2.74, p = 0.001) predicted poor DFS on multivariate analysis. OS was worse in patients with MSI (HR 1.86, p = 0.020 for Low MSI, HR 3.46, p < 0.001 for high MSI), PNI (HR 2.48, p < 0.001) and ENE (HR 3.02, p = 0.001) on multivariate analysis. Adjuvant treatment improved both OS and DFS.

Conclusion

Select patients with masticator space involvement can benefit from aggressive treatment. Radiation with or without chemotherapy in adjuvant setting can further improve prognosis in these patients.

重新定义 pT4b 口腔粘膜鳞状细胞癌:对特定患者的治疗不能仅限于缓解症状。
目的过去20年的报道表明,经过选择的咀嚼肌间隙受侵患者可以通过手术治疗获得合理的生存率。本研究试图确定经手术治疗的pT4口腔粘膜鳞状细胞癌(BMSCC)患者的无病生存期(DFS)和总生存期(OS)的预后指标。材料和方法本回顾性研究的队列包括213例pT4a/b BMSCC患者,这些患者在2011年8月至2019年12月期间接受了治愈性手术治疗。根据咀嚼肌间隙侵犯(MSI)情况,患者被分为3组,即pT4a组、咀嚼肌和/或翼状肌内侧受累组(低MSI)和翼状肌外侧和/或颞肌受累组(高MSI)。pT4a 组、低 MSI 组和高 MSI 组的 5 年 DFS 分别为 53%、42% 和 21%。这三类患者的5年OS分别为68%、43%和21%。在多变量分析中,MSI(低MSI HR 1.5,p = 0.113;高MSI HR 2.98,p < 0.001)、神经周围侵犯(PNI)(HR 2.17,p = 0.001)和结节外扩展(ENE)(HR 2.74,p = 0.001)预示着较差的DFS。在多变量分析中,MSI(低MSI HR 1.86,p = 0.020;高MSI HR 3.46,p < 0.001)、PNI(HR 2.48,p < 0.001)和ENE(HR 3.02,p = 0.001)患者的OS较差。结论选择性咀嚼肌间隙受累患者可从积极治疗中获益。在辅助治疗中,放疗联合或不联合化疗可进一步改善这些患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.20
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信